Metropolis Acquires Ambika Pathology To Boost Maharashtra Presence
ECONOMY & POLICY

Metropolis Acquires Ambika Pathology To Boost Maharashtra Presence

Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India’s second-largest pathology laboratory chain led by Ameera Shah, has completed its fourth acquisition in the past 10 months with the addition of Dr R.S. Patil’s Ambika Pathology Laboratory in Kolhapur. The NABL-accredited facility has joined the Metropolis network through a Business Transfer Agreement.
Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.
The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.
Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”
Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”
Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India’s second-largest pathology laboratory chain led by Ameera Shah, has completed its fourth acquisition in the past 10 months with the addition of Dr R.S. Patil’s Ambika Pathology Laboratory in Kolhapur. The NABL-accredited facility has joined the Metropolis network through a Business Transfer Agreement.Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code